Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

保荐总结报告书 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 保荐机构名称 华泰联合证券有限责任公司 保荐机构编号 Z26774000 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 栋 B7 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 | | 联系人 | 许超、丁明明 | | 联系电 ...

根据《证券法》、《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为迪哲（江苏）医药股份有限公司 （以下简称"迪哲医药"或"公司"）2023 年度向特定对象发行 A 股股票的保 荐机构，承接公司首次公开发行的原保荐机构中信证券股份有限公司未完成的持 续督导工作，对迪哲医药进行持续督导，并出具本年度持续督导跟踪报告。 一、保荐机构和保荐代表人发现的问题及整改情况 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 2024年年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：迪哲医药 | | --- | --- | | 保荐代表人姓名：许超 | 联系电话：010-56839300 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | 随着研发投入的增加，报告期内公司仍处于亏损状态。公司针对不同靶点研 制多款产品，未来仍需持续较大规模的研发投入用于在研项目完成临床试验、药 学研究、临床前研究及新药上市前准备等产品管线研发业务。此外，公司 ...

Group 1 - Dize Pharmaceutical (688192.SH) reported its Q1 2025 results, with 57 institutional investors holding a total of 334 million shares, representing 80.01% of the company's total equity [1] - The top ten institutional investors collectively hold 73.98% of Dize Pharmaceutical's shares, with a slight increase of 0.11 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 17 funds increased their holdings, accounting for a 0.86% increase, with notable funds including Yongying Medical Innovation Mixed Fund A and Ping An Medical Health Mixed A [2] - Conversely, 13 public funds reduced their holdings, representing a 0.12% decrease, with key funds including Bosera Health Growth and Penghua Innovation Medical Mixed A [2] - Six new public funds disclosed their holdings this period, while 239 funds were not disclosed compared to the previous quarter [2]

Group 1 - The core viewpoint of the articles highlights the significant revenue growth and commercialization progress of DiZhe Pharmaceutical, with a reported revenue of 360 million yuan in 2024, marking a year-on-year increase of 294.24% [1] - The company has successfully launched two commercialized products, which have seen nearly doubled sales revenue, achieving a year-on-year growth of 96% in the first quarter of this year [1] - DiZhe Pharmaceutical has established a competitive product pipeline with seven products, including two that are in global clinical trials and have been approved for marketing in China [1][2] Group 2 - In 2024, the company invested 724 million yuan in R&D, accounting for 201.08% of its revenue, with an additional 210 million yuan spent in the first quarter [2] - The company plans to allocate nearly 1 billion yuan from its recent fundraising to the development of core pipeline drugs, including Shuwotini and DZD8586 [2] - DiZhe Pharmaceutical's innovative drug development is characterized by long cycles and high costs, with potential uncertainties in future sales revenue due to various market factors [3] Group 3 - The company is expected to remain unprofitable in the short term, with cumulative losses likely to increase due to ongoing investments in drug registration and market promotion [3] - Analysts believe that DiZhe Pharmaceutical's focus on oncology and innovative products will drive rapid growth in performance as commercialized products gain market traction [3]

Core Insights - Dize Pharmaceutical achieved significant revenue growth in 2024, with operating income reaching 360 million yuan, a year-on-year increase of 294.24%, while the net profit attributable to shareholders was approximately -846 million yuan, a reduction in losses by 24% [1] - In Q1 2025, the company reported operating income of 160 million yuan, a year-on-year growth of 96.32%, with a net profit of approximately -193 million yuan, also showing a reduction in losses by 14% [1] - The company focuses on innovative therapies for malignant tumors and immune diseases, with a competitive product pipeline that includes two leading products in global clinical trials, both of which have been approved for market entry in China and included in the national medical insurance drug list [1] Financial Performance - The sales expense ratio for Q1 2025 was 77%, a significant decrease from the 124% sales expense ratio for the entire year of 2024, indicating improved operational efficiency and effective cost control [2] - The company raised a total of 1.796 billion yuan through a private placement of A-shares, with nearly 1 billion yuan allocated for the research and development of core pipeline drugs including Shuwotai and Gaoruizhe [3] Strategic Developments - The company has established a dedicated commercialization team focused on lung cancer and hematological tumor products, creating a nationwide sales network to meet the growing market demand driven by medical insurance expansion [1] - The CEO highlighted the expectation of record growth in the first year of medical insurance coverage for the two commercialized products, emphasizing the commitment to maximizing shareholder returns through efficient commercial operations [2] - Shuwotai's new drug application has been accepted by the FDA and is under priority review, with ongoing global multi-center Phase III clinical trials advancing [2]

Core Viewpoint - The company has made significant progress in the commercialization of its innovative drugs, with two products included in the National Medical Insurance Directory, leading to substantial revenue growth and reduced net losses. Financial Performance - In Q1 2025, the company achieved revenue of 160 million yuan, a year-on-year increase of 96.32% compared to Q1 2024 [5] - The company reported a net loss attributable to shareholders of 317.2 million yuan, a decrease from the previous year [5] - For the full year 2024, the company recorded sales revenue of 360 million yuan, a year-on-year increase of 294.24% [13] Product Development and Regulatory Approvals - The company's products, Shuwozhe® and Gaoruizhe®, received approval for inclusion in the National Medical Insurance Directory in November 2024, effective from January 1, 2025 [5] - Shuwozhe®'s New Drug Application (NDA) was accepted by the FDA in January 2025, with priority review status granted for treating specific types of lung cancer [6][14] - The company has made advancements in clinical research, with multiple presentations at major conferences, including the European Lung Cancer Conference and the American Society of Clinical Oncology [6][7] Research and Development - The company invested 724 million yuan in R&D in 2024, a decrease of 10.17% year-on-year, focusing on advancing clinical trials and new product development [38] - The company is developing several innovative drugs targeting various cancers, including DZD8586 and DZD6008, which are in different stages of clinical trials [19][20][21] Market and Industry Context - The global oncology drug market is expected to grow significantly, with projections of reaching 419.8 billion USD by 2030, driven by an increasing patient population and rising healthcare expenditures [27][28] - The company operates in a highly competitive and innovative sector, focusing on first-in-class and best-in-class drug development to meet unmet clinical needs [32][31]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-24 迪哲（江苏）医药股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟续聘的会计师事务所名称：立信会计师事务所（特殊普通合伙）（以下 简称"立信"） 一、拟续聘会计师事务所的基本情况 （一） 机构信息 1. 基本信息 立信由我国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年 成为全国首家完成改制的特殊普通合伙制会计师事务所，注册地址为上海市，首席 合伙人为朱建弟先生。立信是国际会计网络 BDO 的成员所，长期从事证券服务业 务，新证券法实施前具有证券、期货业务许可证，具有 H 股审计资格，并已向美 国公众公司会计监督委员会（PCAOB）注册登记。 截至 2024 年末，立信拥有合伙人 296 名，注册会计师 2,498 名，从业人员总 数 10,021 名，签署过证券服务业务审计报告的注册会计师 743 名。2024 年业务收 入（经审计）47.48 亿元，其中审计业务收入 ...

迪哲（江苏）医药股份有限公司 关于 2024 年度"提质增效重回报"行动方案的年度评估报告 以及推动 2025 年度"提质增效重回报"行动方案 为贯彻中央经济工作会议、中央金融工作会议精神，践行以投资者为本的理念， 推动上市公司持续优化经营、规范治理和积极回报投资者，迪哲（江苏）医药股份 有限公司（简称"公司"）基于 2024 年度"提质增效重回报"行动方案取得显著成 效的基础上，结合公司战略规划与行业发展趋势，制定了 2025 年度行动方案，旨 在进一步提升经营质量、强化核心竞争力，为股东创造长期价值，助力公司迈向高 质量发展的新征程。 一、2024 年度"提质增效重回报"行动方案的年度评估 公司是一家创新型生物医药企业，专注于恶性肿瘤、免疫性疾病领域创新疗法 的研究、开发和商业化。公司坚持源头创新的研发理念，以推出全球首创药物 （First-in-class）和具有突破性潜力的治疗方法为目标，旨在填补全球未被满足的 临床需求。2024 年，公司围绕"聚焦主业、创新驱动、优化治理、回馈股东"四 大核心目标，取得显著成效： DZD6008 是一款公司自主研发的、全新的、高选择性 EGFR TKI，可完全穿透 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-23 迪哲（江苏）医药股份有限公司 2024年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所上市公司自律监管指引第1号——规范运作》和《上海证 券交易所科创板股票上市规则》等有关规定，迪哲（江苏）医药股份有限公司 （以下简称"迪哲医药"或"公司"）就2024年度募集资金存放与使用情况专项报 告说明如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意迪哲（江苏）医药股份有 限公司首次公开发行股票注册的批复》（证监许可[2021]3494号）以及上海证 券交易所出具的《关于迪哲（江苏）医药股份有限公司人民币普通股股票科创 板上市交易的通知》（[2021]468号），公司已向社会公众首次公开发行人民币 普通股（A股）40,000,100股（以下简称"本次发行"），每股发行价格为52.58 元，股款以人民币缴足，募集资金总 ...